BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:As neuroscience R and D surges with investment to solve the fi
 eld's most pressing challenge\, access to the brain\, the 5th CNS Drug De
 velopment Summit will provide an unmissable showcase of the latest innova
 tions to revolutionize therapeutic administration routes to the brain and
  optimize dose specificity. Join neuroscientists\, neurobiologists\, neur
 o-oncologists\, protein engineers\, biochemists\, and CNS device experts 
 from the likes of Roche\, AbbVie\, Takeda\, Lundbeck\, Sanofi\, Biogen\, 
 Alnylam Pharmaceuticals and Bristol Myers Squibb this December as they re
 unite to translate their novel brain delivery technologies into the clini
 c.&nbsp\;\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1879346-2?pid=185Br
 ochure:&nbsp\;https://go.evvnt.com/1879346-3?pid=185\n\nPrices:Drug Devel
 oper Pricing - Conference + Workshop Day: USD 4096.00\,Drug Developer Pri
 cing - Conference Only: USD 2599.00\,Solution Provider Pricing - Conferen
 ce + Workshop Day: USD 6046.00\,Solution Provider Pricing - Conference On
 ly: USD 3799.00\n\nSpeakers:&nbsp\;Adem Koksal\, Scientific Director\, Bi
 ologics Drug Discovery\, Biogen\, Allan Jensen\, Vice President\, Lundbec
 k\, Aloïse Mabondzo\, Co-Founder\, CERES Brain Therapeutics\, Anu Bhattac
 haryya\, Executive Director\, PTC Therapeutics\, Bellos Hadjivassiliou\, 
 Senior Principal Scientist\, Bristol-Meyers Squibb\, Bryn Martin\, Vice P
 resident\, Research\, Precision Delivery and CSF Sciences\, Alcyone Thera
 peutics\, Cheng-Chia Wu\, Assistant Professor\, Columbia University Irvin
 g Medical Center\, Darin Falk\, Chief Scientific Officer\, Lacerta Therap
 eutics\, Didier Lefebvre\, Research Fellow\, Abbvie\, Felix Schumacher\, 
 Program Leader Targeted Therapeutics\, Roche\, Fergus Quigley\, Director\
 , Device Development Leader (Early Stage)\, Takeda\, Habib Baghirov\, Sci
 entific Lead\, Roche\, Haiyan Peng\, Principal Scientist\, Alnylam Pharma
 ceuticals\, Iosif Pediaditakis\, Associate Director of Neuroscience\, Alc
 hemab Therapeutics\, Jeff Kurz\, Associate Director\, Alnylam Pharmaceuti
 cals\, Keri Kasun\, Associate Medical Director\, Biogen\, Leah Sabin\, Ex
 ecutive Director\, Regeneron\, Max Nowak\, Senior Scientist\, Viridian Th
 erapeutics\, Nathalie Agar\, Associate Professor of Neurosurgery and of R
 adiology\, Harvard Medical School\, Niels Janssen\, Group Head DMPK/PD\, 
 Roche\, Panna Sharma\, Chief Executive Officer\, Lantern Pharma\, Patrick
  Wen\, Professor of Neurology\, Harvard Medical School\; Director\, Cente
 r For Neuro-Oncology\, Dana-Farber Cancer Instutute\, &nbsp\;Dana-Farber 
 Cancer Institute\, Quan Jin\, Senior Scientist - Gene Therapy Accelerator
  Unit\, Biogen\, Sabyasachi Dash\, Senior Scientist\, Alexion-AstraZeneca
  Rare Disease\, Shyam Ramachandran\, Senior Group Head\, Neurologic Disea
 ses\, Sanofi\, Smrithi Padmakumar\, Drug Product Development Senior Scien
 tist\, Spark Therapeutics\, Stephan Mittermeyer\, Vice President\, Therap
 eutic Strategies\, CNS Gene Therapy\, Asklepios BioPharmaceutical (AskBio
 )\, Suganya Selvarajah\, Director of Biology\, Attralus\, William Elmquis
 t\, Distinguished Professor\, Department of Pharmaceutics\, University of
  Minnesota\n\nTime:&nbsp\;8:00 am to 5:00 pm\n
DTEND:20231207T170000
DTSTAMP:20260307T151839Z
DTSTART:20231205T080000
LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac
 husetts\, 02128\,
SEQUENCE:0
SUMMARY:As neuroscience R and D surges with investment to solve the field'
 s most pressing challenge\, access to the brain\, the 5th CNS Drug Develo
 pment Summ...
UID:02e57930-55a3-4fa1-b842-f6f8795b513e
END:VEVENT
END:VCALENDAR